A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

319

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

June 27, 2022

Study Completion Date

August 9, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

SP-624

Oral capsule

DRUG

Placebo

Oral capsule

Trial Locations (39)

10036

Manhattan Behavioral Medicine, New York

10312

Richmond Behavioral Associates, Staten Island

11235

SPRI Clinical Trials, Brooklyn

18104

Lehigh Center for Clinical Research, Allentown

20877

CBH Health, Gaithersburg

28211

New Hope Clinical Research, Charlotte

28601

Clinical Trials of America, Hickory

30022

Institute for Advanced Medical Research, Alpharetta

30030

iResearch Atlanta, Decatur

30331

Atlanta Center for Medical Research, Atlanta

32256

Clinical Neuroscience Solutions, Inc., Jacksonville

32607

Sarkis Clinical Trials, Gainesville

32801

Clinical Neuroscience Solutions, Inc., Orlando

33319

Innovative Clinical Research, Lauderhill

38119

Clinical Neuroscience Solutions, Inc., Memphis

45417

Midwest Clinical Research Center, Dayton

60048

Capstone Clinical Research, Libertyville

60612

American Medical Research, Chicago

63304

Midwest Research Group, Saint Charles

72211

Woodland International Research Group, Little Rock

72758

Woodland Research Northwest, Rogers

73116

Cutting Edge Research Group, Oklahoma City

75231

Future Search Trials of Dallas, Dallas

76309

Grayline Research Center, Wichita Falls

77090

Red Oak Psychiatry Associates, Houston

78737

Donald J. Garcia, Jr., MD, PA, Austin

80910

MCB Clinical Research Centers, Colorado Springs

85012

Alea Research, Phoenix

89102

Altea Research Institute, Las Vegas

90502

Collaborative Neuroscience Research, Torrance

92103

Artemis Institute for Clinical Research, San Diego

92845

Collaborative Neuroscience Research, Garden Grove

94607

Pacific Research Partners, Oakland

97214

Oregon Center for Clinical Investigations, Portland

97301

Oregon Center for Clinical Investigations, Salem

98201

Core Clinical Research, Everett

08009

Hassman Research Institute, Berlin

08002

Center for Emotional Fitness, Cherry Hill

08053

Hassman Research Institute, Marlton

All Listed Sponsors
lead

Sirtsei Pharmaceuticals, Inc.

INDUSTRY

NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder | Biotech Hunter | Biotech Hunter